Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-10-27
2010-02-02
Crane, Lawrence E (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07655637
ABSTRACT:
2-adenosine N-pyrazole compounds having the following formula:wherein R1═CH2OH; R2is hydrogen; R3is selected from the group consisting of CO2R20; —CONR7R8,and aryl wherein the aryl substituent is optionally substituted with one substituent selected from the group consisting of halo, C1-3alkyl and OR20;R4is hydrogen; R7is selected from hydrogen, and C1-3alkyl; R8is hydrogen; and R20is selected from hydrogen and methyl as well as methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart are disclosed.
REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 4326525 (1982-04-01), Swanson et al.
patent: 4902514 (1990-02-01), Barclay et al.
patent: 4956345 (1990-09-01), Miyasaka et al.
patent: 4968687 (1990-11-01), Hutchison
patent: 4992445 (1991-02-01), Lawter et al.
patent: 5001139 (1991-03-01), Lawter et al.
patent: 5032252 (1991-07-01), Owen et al.
patent: 5070877 (1991-12-01), Mohiuddin et al.
patent: 5189027 (1993-02-01), Miyashita et al.
patent: 5270304 (1993-12-01), Kogi et al.
patent: 5459254 (1995-10-01), Yamaguchi et al.
patent: 5593975 (1997-01-01), Cristalli
patent: 5616345 (1997-04-01), Geoghegan et al.
patent: 5705491 (1998-01-01), Yamada
patent: 5770716 (1998-06-01), Khan et al.
patent: 5877180 (1999-03-01), Linden et al.
patent: 5939543 (1999-08-01), Morozumi et al.
patent: 6026317 (2000-02-01), Verani
patent: 6214807 (2001-04-01), Zablocki et al.
patent: 6294522 (2001-09-01), Zablocki et al.
patent: 6322771 (2001-11-01), Linden et al.
patent: 6368573 (2002-04-01), Leung
patent: 6403567 (2002-06-01), Zablocki et al.
patent: 6448235 (2002-09-01), Linden et al.
patent: 6514949 (2003-02-01), Linden et al.
patent: 6552023 (2003-04-01), Zablocki et al.
patent: 6599283 (2003-07-01), Marzilli et al.
patent: 6605597 (2003-08-01), Zablocki et al.
patent: 6642210 (2003-11-01), Zablocki et al.
patent: 6677336 (2004-01-01), Zablocki
patent: 6770634 (2004-08-01), Zablocki et al.
patent: 6855818 (2005-02-01), Zablocki et al.
patent: 7109180 (2006-09-01), Zablocki et al.
patent: 7144872 (2006-12-01), Zablocki et al.
patent: 7183264 (2007-02-01), Zablocki et al.
patent: 2002/0012946 (2002-01-01), Zablocki et al.
patent: 2002/0111327 (2002-08-01), Linden et al.
patent: 2002/0147174 (2002-10-01), Jones et al.
patent: 2004/0038928 (2004-02-01), Zablocki et al.
patent: 2004/0064039 (2004-04-01), Belardinelli
patent: 2004/0127533 (2004-07-01), Hart et al.
patent: 2004/0137533 (2004-07-01), Belardinelli
patent: 2004/0198692 (2004-10-01), Zablocki et al.
patent: 2005/0020915 (2005-01-01), Belardinelli et al.
patent: 2005/0175535 (2005-08-01), Belardinelli
patent: 2006/0052332 (2006-03-01), Zablocki et al.
patent: 2006/0084625 (2006-04-01), Gordi et al.
patent: 2007/0207978 (2007-09-01), Zablocki et al.
patent: 2007/0299089 (2007-12-01), Belardinelli
patent: 2008/0170990 (2008-07-01), Lieu et al.
patent: 2008/0213165 (2008-09-01), Lieu et al.
patent: 2008/0267861 (2008-10-01), Lieu et al.
patent: 965411 (1975-04-01), None
patent: 0 354 638 (1990-02-01), None
patent: S48 26038 (1973-08-01), None
patent: HEI 5 1993 9197 (1993-01-01), None
patent: WO 93/25677 (1993-12-01), None
patent: WO 98/52611 (1998-11-01), None
patent: WO 98/57651 (1998-12-01), None
patent: WO 99/63938 (1999-12-01), None
patent: WO 00/78778 (2000-12-01), None
patent: WO 00/78779 (2000-12-01), None
patent: WO 01/62979 (2001-08-01), None
patent: WO 2004/011010 (2004-02-01), None
patent: WO 2005/082379 (2005-09-01), None
Glover et al., “Pharmacological Stress Thallium Scintigraphy with 2-Cyclohexylmethylidenehydrazinoadensoine (WRC-0470),” Circulation, 94, 1726-1732 (1996): originally cited in related case U.S. Appl. No. 11/070,768.
Korolkovas, A, Essentials of Molecular Pharmacology—Background for Drug Design, Wiley-Interscience, New York, NY, 1970, only pp. 266-272 supplied.: originally cited in related case U.S. Appl. No. 11/070,768.
Cerqueira, “The future of pharmacologic stress: selective A2A adenosine receptor agonists”, Am. J. Cardiol, vol. 94, no. suppl, 2004 pp. 33D-42D.
Cristalli et al., “2-Alkynl Derivatives of Adenosine 5′-N′ethyluronamide: Selective A2 Adenosine Receptor Agonists with Potent Inhibitory Activity on Platelet Aggregation”, J. Med. Chem., 37:1720-1726 (1994).
Gao, et al., “Novel Short-Acting A2A Adenosine Receptor Agonists for Coronary Vasodilation: Inverse Relationship between Affinity and Duration of Action of A2A Agonists”, Journal of Pharmacology and Experimental Therapeutics, vol. 298, pp. 209-218 (2001).
Glover et al. “Characterization of a New, Highly Selective Adenosine A2A Receptor/Agonists with Potential Use in Pharmacologic Stress Perfusion Imaging”, Circulation, vol. 110, pp. I-311 (1999), Abstract No. 1626.
Hendel et al. “Initial Clinical Experience with Regadenoson, a Novel Selective A2A Agonist for Pharmacologic Stress Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging”, Journal of the American College of Cardiology, vol. 46, No. 11, pp. 2069-2075 (Dec. 6, 2005).
Hendel et al., “Pharmacologic Stress SPECT Myocardial Perfusion Imaging with a Selective A2A Agonist: Results of a Pilot Study Comparing Adenosine with CVT-3146”, Circulation, Supplement IV, vol. 108, (2003), Abstr. No. IV-636.
Iskandrian, A, “Adenosine Myocardial Perfusion Imaging”, The Journal of Nuclear Medicine, vol. 35, pp. 734-736 (1994).
Kerensky et al. “Dose Dependent Increase in Human Coronary Blood Flow Velocity Following an IV Bolus of CVT-3146, A Novel A2A Adenosine Receptor Agonists: A Potential Agent for the Use in Pharmacological Stress Testing for Myocardial Perfusion Imaging”, Circulation, vol. 106, p. II-618 (2002).
Zhao et al., “Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonists” Journal of Cardiovascular Pharmacology, vol. 49, No. 6, pp. 369-375 (Jun. 2007).
Kusmic et al., “Coronary microcirculatory vasoconstriction induced by low-flow ischemia in mouse hearts is reversed by an A2A adenosine receptor”, FASEB Journal, Apr. 2007, A1227-A1228.
Koepfli et al., “Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by PET”, European Heart Journal, vo. 27, No. Supp. 1, p. 175 (Aug. 2006).
Mager, et al., “Molecular simulation applied to 2-(N′alkylidenehydrazino)- and 2-(N′-aralkylidenehydrazino) adenosine A2 Agnonists”, Eur J. Med. Chem, 30:15-25 (1995).
Martin et al., “Pharmacology of 2-cylohexylmethylidenehydrazionoadenosine (WRC-0470), a novel, short-acting adenosine A-2A receptor agonist that produces selective coronary vasodilation”, Drug Development Research, vol. 40, No. 4, pp. 313-324 (1997).
Marumoto, et al., “Synthesis and Coronary Vasodilating Activity of 2-Substituted Adenosines”, Chem.. Pharm. Bull. 23 (4): 759-774 (1975).
Marumoto, et al., “Synthesis and Enzymatic Activity of Adenosine 3′,5′-Cyclic Phosphate Analogs”, Chem.. Pharm. Bull. 27(4) 990-1003 (1979).
Matsuda, et al., “Nucleosides and Nucleotides. 103. 2-Alkynyladenoines: A Novel Class of Selective Adenosine A2 Receptor Agonists with Potent Antihypertensive Effects”, J. Med. Chem. 35:241-252 (1992).
Persson, et al., “Synthesis and Antiviral Effects of 2-Heteroaryl Substituted Adenosine and 8-Heteroaryl Substituted Guanosine Derivatives”, Bioorganic & Medicinal Chemistry, 3:1377-1382 (1995).
Riou et al., “Influence of propranolol, enalaprilat, verapamil, and caffeine on adenosine A(2A) receptor medicated coronary vasodilation”, Journal of the American College of Cardiology, vol. 40, No. 9, pp. 1687-1690 (Nov. 6, 2002).
Swinyard et al., “Pharmaceutical Necessities,” Chapter 66 in Remington's Pharmaceutical Scienc
Belardinelli Luiz
Elzein Elfatih O.
Palle Venkata
Zablocki Jeff A.
Crane Lawrence E
Gilead Palo Alto, Inc.
Swiss Tanner, P.C.
LandOfFree
N-pyrazole A 2A receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-pyrazole A 2A receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-pyrazole A 2A receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4170235